Triomics Raises $22M to Implement Oncology-Focused AI in Cancer Centers

Triomics, a nascent startup focused on developing an AI-powered platform to support oncologists and administrative staff in automating data-heavy tasks such as clinical trial matching and appointment setup, has successfully raised $22 million in Series B funding.

This funding round was spearheaded by Battery Ventures, with backing from returning investors like Nexus Venture Partners, Lightspeed, Y Combinator, and others.

The encouraging news is that progress in oncology allows patients to enjoy longer lives. However, this positive trend leads to intricate, multi-year medical records that healthcare professionals require significant time to analyze and comprehend.

A typical medical chart can include physician progress notes, imaging and pathology reports, and even fax copies. “We have encountered medical records that contain thousands of pages of information,” noted Triomics co-founder Sarim Khan in an interview with TechCrunch.

Established in 2021, Triomics previously secured $15 million in a Series A round in mid-2024. Initially, the startup aimed at helping physicians find the most suitable clinical trials for their patients. However, with advancements in large language model (LLM) capabilities, the platform has broadened its functionality. Over the past couple of years, Triomics has added verifiable patient summaries to its platform, presenting essential information directly within existing clinical tools, allowing clinicians to avoid switching applications.

By optimizing appointment preparation, these summaries enable oncologists to devote more time to their patients. The efficiency gains span beyond individual appointments: in oncology, where patient histories are particularly complex and staff fatigue is a persistent issue, solutions that reduce administrative workloads significantly enhance overall productivity.

Triomics is also employed to automate the tedious process of submitting tumor reports to government registries, which is a legal requirement for cancer centers.

While generic AI agents excel at providing basic summaries, renowned institutions like Memorial Sloan Kettering (MSK) and Yale Cancer Center prefer Triomics due to its models being specifically tailored to oncology data, as explained by Khan.

Triomics faces its closest competition from AI medical scribes like Abridge and Microsoft’s Nuance—tools designed to use AI for documenting conversations between patients and doctors when summarizing patient charts.

Despite fierce competition, Triomics is experiencing rapid growth. According to Khan, the startup has quadrupled its enterprise customer base over the past year, leading to a tenfold increase in annual recurring revenue.

Pictured left to right: Sarim Khan, co-founder and CEO of Triomics, and Hrituraj Singh, co-founder and CTO of Triomics.